Navigation Links
Chronic Migraine Is Associated With Reduced Household Income and Greater Headache Impact
Date:10/29/2010

CHICAGO, Oct. 29 /PRNewswire-USNewswire/ -- New data presented today at The 2010 European Headache and Migraine Trust International Congress (EHMTIC) shows that persons with chronic migraine (headache on greater than or equal to 15 days per month) are much more likely to have annual household incomes below $30,000 than those with episodic migraine (headache on < 15 days per month).  This difference in household income may be attributable to the greater adverse headache impact in the chronic migraine group.  Chronic migraine, a condition characterized by headaches more days than not, afflicts about 1 in 50 Americans.  This research is from the American Migraine Prevalence and Prevention Study (AMPP), the largest-ever longitudinal study of headache.

The study involved 373 individuals with chronic migraine and 6,554 with episodic migraine. Those with chronic migraine were more likely to have average annual household incomes below $30,000 than those with episodic migraine (38.3% of chronic migraineurs and 26.5% of episodic migraineurs had household incomes of less than $30,000/year).   The Headache Impact Test (HIT-6) measures the burden of headache in areas including work, school, social life, and feelings such as fatigue, irritability and difficulty with concentration over the previous month.  Those with chronic migraine had an average score of 64 (indicating "severe impact") and those with episodic migraine had an average score of 58 (indicating "substantial impact").

Study co-investigator, Dawn C. Buse, PhD,  Assistant Professor of Neurology at the Albert Einstein College of Medicine and Director of Behavioral Medicine at the Montefiore Headache Center, Bronx, NY, said,  "These results reinforce the fact that the impact of headache is most significant among persons with chronic migraine when compared to persons with episodic migraine.  In addition, we find that headache impact is predicted by headache pain intensity, severity of associated symptoms, and the presence of depression."

The good news according to study co-investigator, Richard B. Lipton, MD, Professor of Neurology at Einstein and Director of the Montefiore Headache Center, is that chronic migraine, its symptoms, and comorbidities including depression and anxiety are very treatable.  Dr. Lipton advises, "Persons living with chronic migraine should speak with a knowledgeable health care professional about available treatments."

Background

The American Migraine Prevalence and Prevention study began in 2004 when questionnaires were mailed to 120,000 U.S. households to identify severe headache sufferers.  A sample of 24,000 severe headache sufferers, identified in 2004, have been followed annually through 2009.  The 2009 survey included the Headache Impact Test (HIT-6), a self administered, six-item questionnaire that measures pain severity, activity limitations, fatigue, irritability and difficulty concentrating due to headache.  Total sum scores range from 36-78 in the following categories: "no/little impact" (<50), "some impact" (50-55), "substantial impact" (56-59), and "severe impact" (60+).

Migraine is a neurological syndrome characterized by severe, painful headaches that are often accompanied by nausea, vomiting, and increased sensitivity to light and sound.  Headaches may last for hours or even days.  The pain is often on one side of the head and pulsating.  Headaches may be preceded by aura: sensory warning signs such as flashes of light, blind spots, tingling in the arms and legs.  

Migraine can place a significant burden on headache sufferers, their families, and society.   And chronic migraine has been demonstrated to have even greater impact than episodic migraine on a range of factors including socioeconomic status (employment status, household income), headache-related-disability (missed time from work, family and leisure activities), health-related quality of life, and direct and indirect medical costs.  It has also been established that those with chronic migraine are more likely to have additional comorbid medical and psychiatric conditions.

Sponsorship: The American Migraine Prevalence and Prevention Study is funded through a research grant to the National Headache Foundation from Ortho-McNeil Neurologics, Inc., Titusville, NJ.  Additional analyses for this work were supported by Allergan Inc., Irvine, CA.

To learn more about severe headaches, visit the National Headache Foundation website at www.headaches.org, or find a headache specialist in your area.


'/>"/>
SOURCE National Headache Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
3. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
4. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
5. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
6. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
9. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
10. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
11. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
Breaking Medicine News(10 mins):